{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-26-032296","form_type":"8-K","ticker":"AVR","cik":"0002011514","company_name":"Anteris Technologies Global Corp.","filed_at":"2026-08-11T23:07:30+00:00","discovered_at":"2026-08-12T10:05:00.503587+00:00","generated_at":"2026-08-12T10:05:39.725951+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Anteris six-month 2026: revenue $1.503M (+28% YoY), net loss widens to $52.1M","bullets":["Six-month revenue $1.503M vs $1.174M prior year; loss attributable to members $52.118M vs $42.698M (22% worse).","Q2 2026 net operating cash outflows $20.8M; R&D expenses $23.4M driven by PARADIGM trial scaling and manufacturing.","CMS granted Medicare reimbursement for PARADIGM trial procedures under TAVR NCD 20.32; U.S. enrollment began May 2026.","Trial active in U.S., Denmark, Netherlands; regulatory clearance secured in Canada and France; ~1,000-patient randomized study.","No dividend proposed; board appointments of Susan Knight and Stephen Denaro during the quarter."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-032296","json":"https://secwatch.observer/filing/0001140361-26-032296.json","markdown":"https://secwatch.observer/filing/0001140361-26-032296.md","text":"https://secwatch.observer/filing/0001140361-26-032296.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2011514/000114036126032296/0001140361-26-032296-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2011514/000114036126032296/ef20079835_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-12T10:05:39.725951+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}